| 1 |
NCT02959658 |
Recruiting |
Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis |
- Primary Progressive Multiple Sclerosis
|
- Drug: Dimethyl Fumarate
- Drug: Placebo Oral Capsule
|
Interventional |
Phase 2 |
- Rigshospitalet, Denmark
- Biogen
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Neuro filament light chain
- Expanded Disability Status Scale (EDSS)
- Timed 25-Foot Walk (T25FW)
- (and 22 more...)
|
90 |
All |
18 Years to 60 Years (Adult) |
NCT02959658 |
FUMAPMS2016 |
FUMAPMS |
November 2016 |
December 2018 |
December 2019 |
November 9, 2016 |
April 9, 2018 |
|
- Danish Multiple Sclerosis Center, Department of neurology
Copenhagen, Denmark
|
| 2 |
NCT01776060 |
Active, not recruiting |
Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study |
- Primary Progressive Multiple Sclerosis
|
- Other: generation of 'omic markers of disease progression
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Other
|
- Generation of 'omic markers of disease progression
|
100 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT01776060 |
Pro00040961 |
|
January 2013 |
February 2020 |
February 2020 |
January 25, 2013 |
February 12, 2018 |
|
- NE Neurology
Concord, North Carolina, United States - The Stedman Center on the Duke Center for Living Campus
Durham, North Carolina, United States - Raleigh Neurology Associates
Raleigh, North Carolina, United States
|
| 3 |
NCT01854359 |
Enrolling by invitation |
Idebenone for Primary Progressive Multiple Sclerosis |
- Multiple Sclerosis
- Primary Progressive Multiple Sclerosis
|
|
Interventional |
Phase 1
Phase 2 |
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary outcome measure that comes out of the pre-determined analysis in the IPPoMS trial will be adopted as primary outcome measure in the IPPoMS-E trial.
|
58 |
All |
18 Years and older (Adult, Senior) |
NCT01854359 |
130088
13-N-0088 |
|
May 11, 2013 |
October 31, 2018 |
August 1, 2019 |
May 15, 2013 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 4 |
NCT00950248 |
Active, not recruiting |
Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis (IPPoMS) |
- Primary Progressive Multiple Sclerosis
|
|
Interventional |
Phase 1
Phase 2 |
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- The primary outcome measure of the IPPOMS is the rate of disability progression, assessed with the Area Under the Curve (AUC) of the CombiWISE scores during the 2-year treatment period.
- Inhibition of individualized rates of enlargement of ventricular volume: effect of idebenone versus placebo on individualized rates of enlargement of segmented volume of lateral and 3rd ventricles
|
85 |
All |
18 Years to 65 Years (Adult) |
NCT00950248 |
090197
09-N-0197 |
|
July 22, 2009 |
April 30, 2018 |
August 1, 2018 |
July 31, 2009 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 5 |
NCT02284568 |
Completed |
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo |
- Primary Progressive Multiple Sclerosis
|
- Drug: Laquinimod
- Drug: Placebo
|
Interventional |
Phase 2 |
- Teva Branded Pharmaceutical Products, R&D Inc.
- Teva Pharmaceutical Industries
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Percent brain volume change (PBVC)
- Time to confirmed disability progression (CDP)
- Change from baseline in timed 25 foot walk
- Number of new T2 brain lesions
|
374 |
All |
25 Years to 55 Years (Adult) |
NCT02284568 |
TV5600-CNS-20006
2014-001579-30 |
|
January 12, 2015 |
May 4, 2017 |
October 1, 2017 |
November 6, 2014 |
February 12, 2018 |
|
- Teva Investigational Site 12966
Phoenix, Arizona, United States - Teva Investigational Site 12967
Newport Beach, California, United States - Teva Investigational Site 12962
San Francisco, California, United States - (and 96 more...)
|
| 6 |
NCT01194570 |
Active, not recruiting
Has Results |
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis |
- Multiple Sclerosis, Primary Progressive
|
- Drug: Ocrelizumab
- Other: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 12 Weeks During the Double-Blind Treatment Period
- Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 24 Weeks During the Double-Blind Treatment Period
- Percent Change From Baseline in Timed 25-Foot Walk (T25-FW) at Week 120
- (and 4 more...)
|
732 |
All |
18 Years to 55 Years (Adult) |
NCT01194570 |
WA25046
2010-020338-25 |
|
March 2, 2011 |
July 23, 2015 |
April 29, 2021 |
September 3, 2010 |
December 26, 2017 |
December 26, 2017 |
- Phoenix Neurological Associates Ltd
Phoenix, Arizona, United States - Barrow Neurology Clinic
Phoenix, Arizona, United States - Hope Research Institute
Phoenix, Arizona, United States - (and 216 more...)
|
| 7 |
NCT02807285 |
No longer available |
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis |
|
|
Expanded Access |
|
|
Industry |
|
|
|
All |
18 Years to 55 Years (Adult) |
NCT02807285 |
ML29972 |
|
|
|
|
June 21, 2016 |
September 7, 2017 |
|
- Phoenix Neurological Associates Ltd
Phoenix, Arizona, United States - Territory Neurology and Research Institute
Tucson, Arizona, United States - Mercy Medical Group; MS Centre Nurse
Carmichael, California, United States - (and 53 more...)
|
| 8 |
NCT02016222 |
Completed |
Tear Analysis in the Diagnosis of Multiple Sclerosis |
- Primary Progressive Multiple Sclerosis
|
- Procedure: tears sampling
|
Interventional |
Not Applicable |
- Lille Catholic University
- Bayer
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Concordance between the quantification of oligoclonal IgG bands by isoelectric focusing in tears and in the cerebrospinal fluid in patients with primary progressive multiple sclerosis
- Isoelectrophoretic profile of tears
- Isoelectrophoretic profiles of tears by digital recording and analysis of images
|
80 |
All |
18 Years and older (Adult, Senior) |
NCT02016222 |
RC-P0006 |
LARMES |
April 2011 |
March 2016 |
March 2016 |
December 19, 2013 |
September 20, 2016 |
|
- Centre hospitalier universitaire (CHU), Nice
Nice, Alpes Maritimes, France - Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL)
Lille, Nord, France - Centre hospitaliere universitaire
Bordeaux, France - (and 10 more...)
|
| 9 |
NCT00731692 |
Terminated
Has Results |
This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS. |
- Primary Progressive Multiple Sclerosis
|
- Drug: FTY720
- Drug: Placebo
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Kaplan-Meier Estimate of the Risk of 3-month Confirmed Disability Progression Based on Composite Endpoint
- Kaplan-Meier Estimate of the Risk of 3- Month Confirmed Disability Progression Based on Expanded Disability Status Scale (EDSS)
- Percent Change From Baseline in Brain Volume at Month 36
- (and 12 more...)
|
970 |
All |
25 Years to 65 Years (Adult) |
NCT00731692 |
CFTY720D2306
2007-002627-32 |
INFORMS |
July 28, 2008 |
June 22, 2015 |
June 22, 2015 |
August 11, 2008 |
June 14, 2017 |
June 14, 2017 |
- Novartis Investigative Site
Newport Beach, California, United States - Novartis Investigative Site
Sacramento, California, United States - Novartis Investigative Site
Aurora, Colorado, United States - (and 154 more...)
|
| 10 |
NCT02913157 |
Recruiting |
Hydroxychloroquine in Primary Progressive Multiple Sclerosis |
- Multiple Sclerosis, Primary Progressive
|
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Timed 25-Foot Walk (T25FW)
- 9-Hole Peg Test
- Symbol Digit Modalities Test
- (and 3 more...)
|
35 |
All |
18 Years to 65 Years (Adult) |
NCT02913157 |
HCQ_MS01 |
|
November 2016 |
October 2020 |
December 2020 |
September 23, 2016 |
October 27, 2017 |
|
- MS Clinic Foothills Medical Centre
Calgary, Alberta, Canada
|
| 11 |
NCT03362294 |
Recruiting |
Safety and Efficacy of Monthly Long-acting IM Injection of 40 mg GA Depot in Subjects With PPMS |
- Primary Progressive Multiple Sclerosis
|
- Drug: GA Depot 40mg once monthly
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety (Adverse Events and Injection Site Reactions)
- Efficacy (Confirmed Disease Progression)
- Efficacy (Whole brain volume change)
- Efficacy (Cortical volume change)
|
24 |
All |
18 Years to 65 Years (Adult) |
NCT03362294 |
PPMS-GA Depot 002 |
|
December 11, 2017 |
December 2019 |
December 2019 |
December 5, 2017 |
April 18, 2018 |
|
- Barzilai MC
Ashkelon, Israel - Assaf Harofeh MC
Be'er Ya'aqov, Israel - Bnai Zion MC
Haifa, Israel - (and 2 more...)
|
| 12 |
NCT00087529 |
Completed
Has Results |
A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis |
|
- Drug: placebo
- Drug: rituximab
|
Interventional |
Phase 2
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Time to Confirmed Disease Progression (CDP)
- Percentage of Participants With CDP
- Change From Baseline to Week 96 in Total Volume of Transverse Relaxation Time (T2) Brain Lesions on Magnetic Resonance Imaging (MRI) Scan
- Change From Baseline to Week 96 in Brain Volume on MRI Scan
|
439 |
All |
18 Years to 65 Years (Adult) |
NCT00087529 |
U2786g |
OLYMPUS |
June 2004 |
October 2007 |
|
July 13, 2004 |
September 9, 2015 |
September 9, 2015 |
|
| 13 |
NCT02688985 |
Recruiting |
Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) |
- Relapsing Multiple Sclerorsis
- Multiple Sclerosis, Primary Progressive
|
- Drug: Ocrelizumab
- Procedure: Lumber Puncture
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change From Baseline in Neurofilament Light (NfL) Levels in Cerebrospinal Fluid (CSF) Post-Treatment With Ocrelizumab
- Change From Baseline in Number of Cluster of Differentiation (CD) 19+ B-Cells in CSF Post-Treatment with Ocrelizumab
- Change From Baseline in Number of CD3+ T-Cells in CSF Post-Treatment With Ocrelizumab
- (and 4 more...)
|
104 |
All |
18 Years to 55 Years (Adult) |
NCT02688985 |
ML29966
2015-004616-37 |
|
July 12, 2016 |
October 11, 2023 |
October 11, 2023 |
February 23, 2016 |
April 17, 2018 |
|
- Stanford University
Palo Alto, California, United States - University of California at San Francisco
San Francisco, California, United States - University Of Colorado
Aurora, Colorado, United States - (and 16 more...)
|
| 14 |
NCT01450488 |
Completed |
Masitinib in Patients With Primary Progressive Multiple Sclerosis (PPMS) or Relapse-free Secondary Progressive Multiple Sclerosis (SPMS) |
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- change in MSFC
- MSFC subcategories
- Expanded Disability Status Scale (EDSS)
- MFSC subcategories
|
35 |
All |
18 Years to 60 Years (Adult) |
NCT01450488 |
AB04011 |
|
June 2005 |
July 2007 |
January 2010 |
October 12, 2011 |
October 12, 2011 |
|
|
| 15 |
NCT01103583 |
Terminated |
Hydroxyurea in Primary Progressive Multiple Sclerosis |
|
- Drug: Hydroxyurea
- Other: placebo
|
Interventional |
Phase 2
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- the evaluation of safety and tolerability of hydroxyurea
- the evaluation of efficacy of hydroxyurea in primary progressive multiple sclerosis
|
33 |
All |
18 Years to 60 Years (Adult) |
NCT01103583 |
2008-008521-29 |
|
July 2011 |
December 2013 |
|
April 14, 2010 |
February 11, 2014 |
|
- Centre for Experimental Neurological Therapies (CENTERS), Tor Vergata University Hospital
Rome, Italy - Centre for Experimental Neurological Therapies (CENTERS), S.Andrea Hospital
Rome, Italy
|
| 16 |
NCT01339234 |
Completed |
Supported Treadmill Training for Progressive Multiple Sclerosis |
|
- Other: Body-weight supported treadmill training
|
Interventional |
Not Applicable |
- Hicks, Audrey, Ph.D.
- Multiple Sclerosis Society of Canada
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Change from baseline in Multiple Sclerosis Functional Composite (MSFC) at 12, 24 and 36 weeks
- Change from baseline in Expanded Disability Status Scale (EDSS) at 12, 24 and 36 weeks
- Change from baseline in Modified Fatigue Impact Scale (MFIS) at 12, 24 and 36 weeks
- (and 3 more...)
|
6 |
All |
18 Years to 60 Years (Adult) |
NCT01339234 |
Hicks -MS treadmill |
|
April 2008 |
June 2009 |
June 2009 |
April 20, 2011 |
April 20, 2011 |
|
- McMaster University (Centre for Health Promotion and Rehabilitation)/Hamilton Health Sciences
Hamilton, Ontario, Canada
|
| 17 |
NCT03455582 |
Not yet recruiting |
Cognition Evolution and MRI Markers in PPMS Patients on 2 Years |
- Multiple Sclerosis, Primary Progressive
|
- Other: Clinical assessment
- Other: Ecological evaluation
- Other: Neuropsychological evaluation
- (and 2 more...)
|
Interventional |
Not Applicable |
- University Hospital, Bordeaux
- Roche Pharma AG
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Change of composite z cognitive score based on individual neuropsychological scores
- Correlation of composite z cognitive score and ecological score with MRI parameters reflecting grey and white matter integrity and anatomic/functional connectivity
- Changes of composite z ecological score based on individual ecological scores
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT03455582 |
CHUBX 2017/14 |
PRO-COG |
March 2018 |
March 2022 |
March 2022 |
March 6, 2018 |
March 6, 2018 |
|
- CHU de Bordeaux
Bordeaux, France - CHU de Limoges
Limoges, France - CHU de Poitiers
Poitiers, France
|
| 18 |
NCT01077466 |
Completed |
Natalizumab Treatment of Progressive Multiple Sclerosis |
- Primary Progressive Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis
|
|
Interventional |
Phase 2 |
- Rigshospitalet, Denmark
- Copenhagen University Hospital, Hvidovre
- Biogen
- (and 2 more...)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cerebrospinal fluid (CSF) osteopontin
- Expanded disability status scale (EDSS)
- Timed 25-foot Walk (T25FW)
- (and 17 more...)
|
24 |
All |
19 Years to 55 Years (Adult) |
NCT01077466 |
NAPMS version 3.4 |
NAPMS |
March 2010 |
January 2012 |
January 2012 |
March 1, 2010 |
February 17, 2012 |
|
- Danish Multiple Sclerosis Center, Section 2082, Rigshospitalet
Copenhagen, Denmark
|
| 19 |
NCT01381354 |
Completed |
Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS) |
|
- Other: Progressive exercise
- Device: Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV
- Other: Modified paleolithic diet
- (and 20 more...)
|
Interventional |
Phase 1 |
- University of Iowa
- Direct MS Canada
- DJO Incorporated
- (and 2 more...)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Fatigue severity scale
- 25 foot walk
- Short Form 36
- (and 39 more...)
|
38 |
All |
18 Years to 65 Years (Adult) |
NCT01381354 |
200911781 |
|
October 2010 |
February 2016 |
May 2016 |
June 27, 2011 |
November 23, 2016 |
|
- Univeristy of Iowa/ VA Iowa City VA Medical Center
Iowa City, Iowa, United States
|
| 20 |
NCT02208050 |
Active, not recruiting |
A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis |
- Secondary Progressive Multiple Sclerosis
- Primary Progressive Multiple Sclerosis
|
- Drug: Fampridine
- Drug: Placebo
|
Interventional |
Phase 4 |
- University College Dublin
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The primary end point will be the number of participants who show an improvement of 20% on the 9 Hole Peg Test (9-HPT) at the end of their treatment period with fampridine. These will be classified as upper limb responders.
- The number of upper limb responders as defined by a 20% improvement in the Jebson Taylor Hand Function Test (JTT) "on treatment" compared to baseline assessments.
- The number of mobility responders to fampridine as measured by an improvement in the 25 foot timed walk (T25FW) "on treatment" compared to "off treatment".
- (and 6 more...)
|
66 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02208050 |
SVUHneuro002 |
|
March 2014 |
December 2017 |
March 2018 |
August 4, 2014 |
May 10, 2017 |
|
- St Vincent's University Hospital
Elm Park, Dublin 4, Ireland - St. Vincents University Hospital
Dublin, Ireland
|
| 21 |
NCT03094364 |
Recruiting |
Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis |
- Primary Progressive Multiple Sclerosis
- Hemiparesis
|
- Behavioral: Gaming CI Therapy
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Bilateral Activity Monitors (Accelerometers)
- Wolf Motor Function Test
- Biomechanical Measures
- (and 5 more...)
|
36 |
All |
18 Years and older (Adult, Senior) |
NCT03094364 |
60052127 |
|
November 2015 |
October 2018 |
October 2018 |
March 29, 2017 |
September 11, 2017 |
|
- The Ohio State University, 2154 Dodd Hall
Columbus, Ohio, United States
|
| 22 |
NCT02253264 |
Completed |
A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients |
- Primary Progressive Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis
|
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of serious adverse events over the course of the study at least possibly related to intrathecal rituximab therapy, as determined by the principal investigator.
|
8 |
All |
18 Years and older (Adult, Senior) |
NCT02253264 |
IRB00027318 |
|
November 2014 |
August 2017 |
August 2017 |
October 1, 2014 |
August 30, 2017 |
|
- The Johns Hopkins Hospital
Baltimore, Maryland, United States
|
| 23 |
NCT02273635 |
Unknown † |
Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS |
- Primary Progressive Multiple Sclerosis
- Multiple Sclerosis, Secondary Progressive
|
- Drug: Andrographolides
- Drug: placebo
|
Interventional |
Phase 1
Phase 2 |
- Innobioscience SpA
- Pontificia Universidad Catolica de Chile
- University of Chile
- Universidad Austral de Chile
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Brain atrophy in patients with progressive forms of MS
- Expanded Disability Status Scale (EDSS)
- Paced Auditory Serial Addition Test (PASAT)
- (and 13 more...)
|
68 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02273635 |
14PIE-26946CORFO
14-391 |
|
September 2014 |
November 2016 |
April 2017 |
October 24, 2014 |
October 27, 2014 |
|
- Multiple Sclerosis Centre, Pontificia Universidad Catolica de Chile
Santiago, Metropolitana, Chile
|
| 24 |
NCT01191996 |
Completed |
Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis |
- Secondary Progressive Multiple Sclerosis
- Primary Progressive Multiple Sclerosis
|
|
Interventional |
Phase 1
Phase 2 |
- Innate Immunotherapeutics
- Primorus Clinical Trials
- National Multiple Sclerosis Society
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety profile, including maximum tolerated dose
- Pharmacodynamic assessments
- MRI assessments
- Clinical status
|
34 |
All |
18 Years and older (Adult, Senior) |
NCT01191996 |
MIS416-201 |
|
August 2010 |
June 2012 |
November 2012 |
August 31, 2010 |
December 7, 2012 |
|
- Primorus Clinical Trials, 40 Stewart Street
Christchurch, Canterbury, New Zealand
|
| 25 |
NCT01433497 |
Recruiting |
A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis |
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis, Relapse Free
|
- Drug: masitinib
- Drug: placebo
|
Interventional |
Phase 2
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- EDSS
- Multiple Sclerosis Quality of Life 54 items (MSQOL-54)
- Multiple Sclerosis Functional Composite (MSFC)
|
450 |
All |
18 Years and older (Adult, Senior) |
NCT01433497 |
AB07002 |
|
August 2011 |
January 2019 |
July 2019 |
September 14, 2011 |
April 21, 2017 |
|
- Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
|
| 26 |
NCT03283826 |
Recruiting |
Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive and Relapsing-Remitting Multiple Sclerosis |
- Relapsing Remitting Multiple Sclerosis
- Primary Progressive Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis
|
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of adverse events and clinically significant changes in laboratory tests, ECGs, and vital signs
- Recommended Phase 2 dose of ATA188 monotherapy
- Change from baseline in the number of Gd-enhancing and new or enlarging T2 lesions on brain MRI scans for subjects with RRMS
- (and 2 more...)
|
60 |
All |
18 Years to 65 Years (Adult) |
NCT03283826 |
ATA188-MS-101 |
|
October 19, 2017 |
March 2020 |
March 2020 |
September 14, 2017 |
March 22, 2018 |
|
- The NeuroMedical Center Clinic
Baton Rouge, Louisiana, United States - Liverpool Hospital
Liverpool, New South Wales, Australia - Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
|
| 27 |
NCT01466114 |
Recruiting |
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition |
- Relapsing-remitting Multiple Sclerosis
- Secondary-progressive Multiple Sclerosis
- Primary-progressive Multiple Sclerosis
|
- Drug: estriol
- Other: Placebo
- Drug: Norethindrone
- Other: Progestin Placebo
|
Interventional |
Phase 2 |
- University of California, Los Angeles
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in cognitive function assessed by Paced Serial Addition Test (PASAT).
- Change from baseline in cognitive function as assessed by cognitive evoked potentials, measured in milliseconds.
- Change from baseline in standard MS outcome measures.
- (and 2 more...)
|
64 |
Female |
18 Years to 55 Years (Adult) |
NCT01466114 |
11-002055 |
|
October 2011 |
November 2018 |
December 2018 |
November 7, 2011 |
April 20, 2017 |
|
- University of California Los Angeles
Los Angeles, California, United States - The University of Colorado Denver
Aurora, Colorado, United States - The University of New Mexico
Albuquerque, New Mexico, United States - The University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
| 28 |
NCT02549703 |
Active, not recruiting |
Mitochondrial Dysfunction and Disease Progression |
- Clinically Isolated Syndrome
- Relapsing-Remitting Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis
- Primary Progressive Multiple Sclerosis
|
|
Observational |
|
- Icahn School of Medicine at Mount Sinai
- Columbia University
- The New York Stem Cell Foundation
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Spare respiratory capacity
- Oxygen consumption rate
- Multiple Sclerosis Functional Composite (MSFC) Score
- (and 2 more...)
|
49 |
All |
18 Years and older (Adult, Senior) |
NCT02549703 |
GCO 14-1495
CDMRP-MS140072 |
|
September 2015 |
September 2018 |
September 2018 |
September 15, 2015 |
July 2, 2017 |
|
- Icahn School of Medicine
New York, New York, United States
|
| 29 |
NCT01538225 |
Completed |
Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity |
|
- Drug: Sativex®
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- H/M reflex ratio
- Neurophysiology ·H/M ratio ·Transcranial Magnetic Stimulation a) MEP Motor threshold, upper limb b) MEPs amplitudes c) Intracortical facilitation/inhibition (ICI/ICF), upper limb
- Adverse Events recording
- (and 3 more...)
|
45 |
All |
18 Years and older (Adult, Senior) |
NCT01538225 |
M/SATIVX/01
2011-002258-30 |
NS-MSS |
April 2012 |
November 2013 |
November 2013 |
February 24, 2012 |
January 20, 2014 |
|
- Institute of Experimental Neurology
Milan, Italy
|
| 30 |
NCT00682929 |
Terminated |
Cannabis for Spasticity in Multiple Sclerosis |
|
- Drug: Inhaled Cannabis
- Drug: Oral THC
- Drug: Placebo
|
Interventional |
Phase 1
Phase 2 |
- University of California, Davis
- National Multiple Sclerosis Society
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- LITO Machine Score
- Ashworth Scale
- Functional System Score
- (and 4 more...)
|
42 |
All |
21 Years and older (Adult, Senior) |
NCT00682929 |
200311404
MS Society Award # RG 3781-A-1 |
|
November 2003 |
February 2015 |
September 2018 |
May 23, 2008 |
October 5, 2017 |
|
- University of California Davis Medical Center
Sacramento, California, United States
|
| 31 |
NCT00260741 |
Terminated |
Cannabis for Spasticity in Multiple Sclerosis |
|
|
Interventional |
Phase 1
Phase 2 |
- Center for Medicinal Cannabis Research
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Change in an objective measurement of spasticity between the pretreatment assessment and the 4- and 8-week assessments.
- Differences between active agent and placebo in the changes in Ashworth Scale, Functional System Score, Expanded Disability Status Score, Ambulation Index, Functional Composite Score, and Quality of Life Inventory.
|
60 |
All |
21 Years and older (Adult, Senior) |
NCT00260741 |
C00-DA-112
200311404-4 |
|
March 2003 |
|
January 2006 |
December 2, 2005 |
April 4, 2007 |
|
- UC Davis Medical Center
Sacramento, California, United States
|
| 32 |
NCT01950234 |
Recruiting |
ACTH in Progressive Forms of MS |
- Secondary Progressive Multiple Sclerosis
- Primary Progressive Multiple Sclerosis
- Progressive Relapsing Multiple Sclerosis
|
|
Interventional |
Phase 2 |
- University of Minnesota - Clinical and Translational Science Institute
- Mallinckrodt
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Proportion of patients exhibiting a 20% worsening in T25FW at 36 months
- Safety and tolerability of ACTH
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT01950234 |
ACTH-20712 |
|
October 2013 |
March 2021 |
March 2022 |
September 25, 2013 |
February 12, 2018 |
|
- Clinical Neuroscience Research Unit, University of Minnesota
Minneapolis, Minnesota, United States - Sanford Clinic Neuroscience
Fargo, North Dakota, United States - Wheaton Franciscan Healthcare - St Francis Center for Neurological Disorders
Milwaukee, Wisconsin, United States
|
| 33 |
NCT01982942 |
Completed |
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis |
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis, Secondary Progressive
|
- Drug: ibudilast
- Drug: Placebo
|
Interventional |
Phase 2 |
- MediciNova
- National Institutes of Health (NIH)
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Multiple Sclerosis Society
|
Industry / NIH / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Covariate-adjusted mean rate of change in brain atrophy over 96 weeks as measured by brain parenchymal fraction (BPF).
- Safety Measures: TEAEs (treatment-emergent adverse events), TESAEs (treatment-emergent serious adverse events), treatment discontinuations due to TEAEs, laboratory measures (chemistry, hematology, urinalysis), vital signs, electrocardiograms (ECGs).
- Diffusion tensor imaging (DTI) in descending pyramidal white matter tracts
- (and 8 more...)
|
255 |
All |
21 Years to 65 Years (Adult) |
NCT01982942 |
NN102 SPRINT - MS
1U01NS082329-01A1
RG 4778-A-6 |
|
November 2013 |
May 2017 |
December 2017 |
November 13, 2013 |
January 31, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - University of California Davis
Davis, California, United States - University of California Los Angeles
Los Angeles, California, United States - (and 25 more...)
|
| 34 |
NCT02845635 |
Recruiting |
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis |
|
- Other: Personal history of multiple sclerosis
|
Observational |
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Change in perceived fatigue severity (self-report) as recorded by symptom diary
- Change in perceived cognitive impairment (self-report) as recorded by symptom diary
- Change in perceived depression or anxiety severity (self-report) as recorded by symptom diary
- (and 11 more...)
|
2000 |
All |
18 Years and older (Adult, Senior) |
NCT02845635 |
Pro00072319 |
|
September 29, 2017 |
August 2025 |
August 2025 |
July 27, 2016 |
October 4, 2017 |
|
- Duke University Medical Center
Durham, North Carolina, United States
|
| 35 |
NCT03493841 |
Not yet recruiting
New |
Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis |
- Multiple Sclerosis
- Progressive Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis
- Primary Progressive Multiple Sclerosis
|
|
Interventional |
Phase 1 |
- Rebecca Spain
- Oregon Health and Science University
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Comparison of oral tolerance between R-LA and racemic LA
- Comparison of serum bioavailability as measured by Area Under the Curve (0-infinity) between R-LA and racemic LA
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT03493841 |
IRB #17951 |
|
April 30, 2018 |
March 31, 2019 |
September 1, 2019 |
April 11, 2018 |
April 11, 2018 |
|
|
| 36 |
NCT02789670 |
Recruiting |
Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients |
- Multiple Sclerosis
- Systemic Sclerosis
|
- Other: Blood sample collection
|
Observational |
|
- University Hospital, Lille
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Comparison of the production of IL-10 and IL-6 by B cells in MS patients and the control group at inclusion time point
- Comparison of the production of IL-10 and IL-6 by B cells in MS patients and the control group at the different time points of the study
- Comparison of the production of IL-10 and IL-6 by B cells in the MS patient subgroups at the inclusion time point
- (and 4 more...)
|
160 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02789670 |
2013_35
2014-A00248-39 |
B-MS |
July 2014 |
July 2018 |
December 2018 |
June 3, 2016 |
May 31, 2017 |
|
- CHRU de Lille
Lille, France
|
| 37 |
NCT01411514 |
Terminated |
Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis |
|
- Drug: Prednisone
- Drug: Placebo
|
Interventional |
Phase 4 |
- Claudio Gobbi
- Ente Ospedaliero Cantonale, Ticino, Switzerland
- Ospedale Civico, Lugano
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Expanded Disability Status Scale (EDSS)
- Multiple Sclerosis Functional Composite Score (MSFC)
- Gd-enhancing lesions on T1-weighted images
- (and 6 more...)
|
27 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT01411514 |
EOC.NC.10.04 |
|
August 2011 |
January 2015 |
January 2015 |
August 8, 2011 |
December 18, 2015 |
|
- Osepdale Civico
Lugano, Ticino, Switzerland
|
| 38 |
NCT01080014 |
Completed |
Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- - Evaluation of correlations between changes over time
- To evaluate the predictive validity of MSFC score of a subsequent EDSS change in a subgroup of MS patients
|
252 |
All |
18 Years to 65 Years (Adult) |
NCT01080014 |
EMR 200077_502 |
|
August 2008 |
April 2013 |
April 2013 |
March 3, 2010 |
October 16, 2013 |
|
- Dr. Roberto Rosa
Buenos Aires, Argentina
|
| 39 |
NCT01915433 |
Completed |
Wahls Paleo Diet and Progressive Multiple Sclerosis |
|
- Other: Wahls Paleo Plus
- Other: Wahls Diet
|
Interventional |
Not Applicable |
- Terry L. Wahls
- University of Iowa
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Perceived Fatigue
- Biomarkers
- Biomarkers - glucose and ketones
- (and 19 more...)
|
15 |
All |
30 Years to 65 Years (Adult) |
NCT01915433 |
201302829 |
|
July 2013 |
February 2014 |
November 2016 |
August 2, 2013 |
March 31, 2017 |
|
- Univeristy of Iowa
Iowa City, Iowa, United States - Univeristy of Iowa
Iowa City, Iowa, United States
|
| 40 |
NCT01723631 |
Terminated |
Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis |
|
|
Interventional |
Not Applicable |
- Nantes University Hospital
- Institut National de la Santé Et de la Recherche Médicale, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Evaluate the diagnostic performance of myelin-TRAP assay for Multiple Sclerosis
- Determine the best cut-off rate of myelin-Trap and evaluate the sensitivity and specificity associated
|
189 |
Female |
18 Years to 55 Years (Adult) |
NCT01723631 |
BRD/10/06-S
2010-A00892-37 |
TRAP-Myéline |
April 2012 |
December 2014 |
October 2015 |
November 8, 2012 |
May 16, 2017 |
|
- University Hospital of Bordeaux
Bordeaux, France - Hopital neurologigue Pierre Wertheimer
Bron, France - University Hospital of clermont Ferrand
Clermont Ferrand, France - (and 8 more...)
|
| 41 |
NCT02220244 |
Active, not recruiting |
Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis |
|
- Drug: MD1003 100mg capsule
|
Interventional |
Phase 3 |
- MedDay Pharmaceuticals SA
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline of the best corrected visual acuity at 100% contrast
- Visual field mean deviation change from baseline
- Reappearance or improvement of the P00 wave on Visual Evoked Potential
- Optical Coherence Tomography
|
105 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02220244 |
MD1003CT2013-01MS-ON
2013-002112-27 |
MS-ON |
October 2013 |
December 2015 |
January 2018 |
August 19, 2014 |
March 27, 2017 |
|
- Hopital Pellegrin
Bordeaux, France - Hopital de la cote de Nacre
Caen, France - Hopital Gabriel Montpied
Clermont Ferrand, France - (and 17 more...)
|
| 42 |
NCT02889965 |
Recruiting |
The French Multiple Sclerosis Registry |
- Multiple Sclerosis
- Neuromyelitis Optica Spectrum Disorders
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of cases of MS included
- number of patients
- demographic characteristics
- (and 3 more...)
|
54000 |
All |
up to 100 Years (Child, Adult, Senior) |
NCT02889965 |
69HCL14_0385 |
OFSEP |
January 2011 |
December 2019 |
December 2019 |
September 7, 2016 |
September 7, 2016 |
|
- Hospices Civils de Lyon / Hopital Neurologique Pierre Wertheimer
Bron, France
|
| 43 |
NCT03424538 |
Enrolling by invitation |
The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis Patients |
- Multiple Sclerosis, Chronic Progressive
- Multiple Sclerosis, Primary Progressive
|
- Other: Neurorehabilitation
- Other: Physiotherapy
|
Interventional |
Not Applicable |
- Somogy Megyei Kaposi Mór Teaching Hospital
- University Medical Center Groningen
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Postural instability
- quality of life
- balance test
- (and 2 more...)
|
2 |
All |
35 Years to 60 Years (Adult) |
NCT03424538 |
IKEB008/2017 |
|
February 5, 2018 |
April 16, 2018 |
June 10, 2018 |
February 7, 2018 |
April 17, 2018 |
|
- Somogy Megyei Kaposi Mór Teaching Hospital
Kaposvár, Somogy, Hungary
|
| 44 |
NCT01804647 |
Completed |
Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease |
- Multiple Sclerosis (MS)
- Relapsing-Remitting MS
- Primary Progressive MS
- (and 2 more...)
|
- Other: No study treatments administered - blood draws only
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Monitor the levels of MSRV-Env expression in MS patients (according to McDonald criteria) of different diagnostic subgroups (RRMS, SPMS, PPMS, CIS)
- Associate the levels of MSRV-Env protein and transcripts
- Associate the levels of MSRV-Env as assessed with the 3 approaches with MS relapses/exacerbations and/or clinical evolution (EDSS score) and /or treatment
- (and 2 more...)
|
58 |
All |
18 Years to 60 Years (Adult) |
NCT01804647 |
GN-E-002 |
LOMBARD |
November 2012 |
February 2015 |
February 2015 |
March 5, 2013 |
March 1, 2018 |
|
- Hospices civils de Lyon - Service de Neurologie A - 59 Boulevard Pinel
Bron cedex, France - CHU Timone - Service de Neurologie et CRMBM CNRS 7339 - 264, rue Saint Pierre
Marseille Cedex 5, France - Hospital Universitari and Research Institute Vall d'Hebron - Servicio de Neuroimunologia de Nuestro Centro - Pg. Vall d'Hebron 119-129
Barcelona, Cataluna, Spain - Centre Hospitalier Universitaire Vaudois - Dpt of Clinical Neurosciences - Neurology /Batiment 10-131 - Rue du Bugnon 46 -
Lausanne, Switzerland
|
| 45 |
NCT02305264 |
Recruiting |
Imaging of Intracerebral Inflammation in MS |
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis, Primary Progressive
|
- Drug: 18F-DPA-714 and 18F-FDG
|
Interventional |
Not Applicable |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Whole brain Binding Potential (BP) of 18F-DPA-714
- Binding potential of 18F-DPA-714 in segmented brain regions
- Binding potential of 18F-DPA-714 in subgroups of MS patients
- (and 2 more...)
|
65 |
All |
18 Years to 65 Years (Adult) |
NCT02305264 |
P091001 |
INFLASEP |
February 2012 |
February 2018 |
February 2018 |
December 2, 2014 |
February 23, 2017 |
|
- Saint Antoine Hospital
Paris, France - Pitie Salpetriere Hospital
Paris, France
|
| 46 |
NCT02896179 |
Not yet recruiting |
Virtual Reality and Robot Assisted Gait Training in Patients With Multiple Sclerosis |
|
- Device: Robot-assisted gait training group+VR
- Device: GEO
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- 10 meters Walking test (10-MtWT) change in gait speed (m/sec)
- Berg Balance Scale
- 2-Minute Walking Test (meters)
- (and 18 more...)
|
20 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02896179 |
GE-O-VR |
GE-O-VR |
November 2016 |
November 2017 |
November 2018 |
September 12, 2016 |
September 26, 2016 |
|
- Azienta Ospedaliera, SSO Rehabilitation Unit, Verona
Verona, Italy
|
| 47 |
NCT01848327 |
Completed |
Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis |
- Relapsing Remitting MS
- Secondary Progressive MS
- Primary Progressive MS
|
- Dietary Supplement: Caprylic Triglyceride
- Dietary Supplement: Placebo
|
Interventional |
Not Applicable |
- University of Miami
- National Multiple Sclerosis Society
- Accera, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Total Learning (Trials 1-5) on the California Verbal Learning Test-2nd Edition (CVLT-II) (range from 0 to 80)
- Change in Symbol Digit Modalities Test (SDMT) (range from 0-110)
- Number of participants reporting adverse events
- (and 4 more...)
|
124 |
All |
18 Years to 59 Years (Adult) |
NCT01848327 |
20120415
5559072 |
|
February 2013 |
December 2017 |
December 2017 |
May 7, 2013 |
January 25, 2018 |
|
- University of Miami Miller School of Medicine
Miami, Florida, United States
|
| 48 |
NCT03332654 |
Completed |
Stress Urinary Incontinence in Women With Multiple Sclerosis |
- Urinary Incontinence, Stress
- Multiple Sclerosis
|
- Other: Determine prevalence of stress urinary incontinence
|
Observational |
|
- Lille Catholic University
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Stress urinary incontinence
|
363 |
Female |
18 Years and older (Adult, Senior) |
NCT03332654 |
OBS-019 |
UROSEP |
February 1, 2015 |
January 31, 2016 |
March 31, 2016 |
November 6, 2017 |
November 6, 2017 |
|
|
| 49 |
NCT02988401 |
Recruiting |
Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis |
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis, Primary Progressive
|
- Drug: Insulin
- Drug: Placebo (Sterile diluent)
|
Interventional |
Phase 1
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in cognitive function as assessed by the Symbol Digit Modalities Test (SDMT)
- Determine safety by assessing the number of subjects with adverse events with treatment as compared to placebo.
- Determine safety by assessing the number of subjects with adverse events with placebo.
- (and 6 more...)
|
105 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02988401 |
IRB00095554 |
|
December 1, 2017 |
December 2018 |
December 2018 |
December 9, 2016 |
December 15, 2017 |
|
- Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
|
| 50 |
NCT02747914 |
Active, not recruiting |
Repetitive Transcranial Magnetic Stimulation for Lower Limb Spasticity in Multiple Sclerosis Patients |
|
- Device: Transcranial magnetic stimulation
- Other: Conventional exercise
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- muscle tone measured by Modified Ashworth Scale (MAS)
- impact of leg spasticity on daily activities measured by Multiple Sclerosis Spasticity Scale 88 (MSSS-88)
- Activities of daily living measured by Barthel Index
- (and 2 more...)
|
40 |
|
Child, Adult, Senior |
NCT02747914 |
LK-5 |
|
January 2015 |
May 2017 |
May 2019 |
April 22, 2016 |
October 26, 2017 |
|
|
Create an RSS feed from your search for:
Download the search results for: